Please select the option that best describes you:
Topics:
Radiation Oncology • Neuro-Oncology • Pediatric Hematology/Oncology • Medical Oncology • Neurology
What approach do you use when treating adult diffuse gliomas with H3-G34 mutations, now classified into their own category under the 2021 glioma guidelines?
Do you treat this similarly to IDH-Wildtype GBM with the STUPP regimen? Is there any role of less-intensive paradigms, such as 59.4 Gy/33 fx?
Answer from: Radiation Oncologist at Academic Institution
Although DHG H3G34-mutant diffuse gliomas are more commonly associated with pediatric patients, they can occur in young adults as well. In a recent paper describing 17 patients harboring this rare mutation, the median age at diagnosis was 25 years (range: 19–33). All tumors were hemispheric. A...
Sign in or Register to read more